Results 1 to 10 of about 97,561 (185)

Pyrazinamide resistance in rifampicin discordant tuberculosis.

PLoS ONE, 2022
IntroductionMycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known
Nomonde Ritta Mvelase, Ravesh Singh, Khine Swe Swe-Han, Koleka Patience Mlisana   +3 more
doaj   +4 more sources

Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain [PDF]

BMC Microbiology, 2010
Background Methicillin-resistant S. aureus (MRSA) has been endemic in Hospital Universitari de Bellvitge, Barcelona, since 1990. During the 1990-95 period the Iberian clone (ST-247; SCCmec-I) was dominant. Isolates of clonal complex 5 (ST-125; SCCmec-IV)
Liñares Josefina, Tubau Fe, Domínguez M Angeles, Mick Virginie, Pujol Miquel, Martín Rogelio   +5 more
doaj   +3 more sources

Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. [PDF]

PLoS ONE, 2016
BACKGROUND:Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on
Leonela Villegas, Larissa Otero, Timothy R Sterling, Moises A Huaman, Patrick Van der Stuyft, Eduardo Gotuzzo, Carlos Seas   +6 more
doaj   +9 more sources

Incidence of Rifampicin Resistance in Periprosthetic Joint Infection: A Single-Centre Cohort Study on 238 Patients [PDF]

Antibiotics, 2023
Background. Rifampicin is a pillar in the treatment of periprosthetic joint infection (PJI). However, rifampicin resistance is an increasing threat to PJI treatment.
Stergios Lazarinis, Nils P. Hailer, Josef D. Järhult, Anders Brüggemann   +3 more
doaj   +2 more sources

Prevalence of rifampicin resistance in pulmonary tuberculosis: A laboratory-based study. [PDF]

PLOS Global Public Health
Tuberculosis (TB) remains a significant global public health challenge, particularly in low- and middle-income countries. The emergence of rifampicin-resistant tuberculosis further complicates control efforts.
Israel Bedzina, Agnes Naa Larley Lartey, Lois Kwaley-Buabeng, Prosper Mensah, Gameli Nudo, Eric Selorm Odum, Rita Sewornu, Kenneth Ablordey, John Gameli Deku, Kwabena Obeng Duedu   +9 more
doaj   +2 more sources

Titanium-tethered vancomycin prevents resistance to rifampicin in Staphylococcus aureus in vitro. [PDF]

PLoS ONE, 2012
Rifampicin is currently recognized as the most potent drug against Gram positive implant related infections. The use of rifampicin is limited by the emergence of bacterial resistance, which is often managed by coadministration of a second antibiotic. The
Martin Rottman, Joel Goldberg, S Adam Hacking   +2 more
doaj   +5 more sources

Navigating a Path to Rifampicin Resistance in Tuberculosis. [PDF]

mBio, 2023
For model bacteria, genetic drug resistance usually arises from antibiotic-tolerant subpopulations, but whether this is true for the globally important pathogen Mycobacterium tuberculosis —the cause of tuberculosis—is not known. Here, we discuss a recent article by Sebastian et al. (J. Sebastian, A.
Agarwal S, Javid B.
europepmc   +6 more sources

Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis. [PDF]

BMC Infect Dis
Although many studies have examined the connection between mutations in the rpoB gene and drug resistance, the impact of common mutations on treatment outcomes for RR-TB is not yet fully understood.This study explores the relationship between rpoB gene mutations and drug-resistant phenotypes, assesses their role in predicting RR-TB prognosis, and ...
Jose Vadakunnel M, Nehru VJ, Brammacharry U, Ramachandra V, Palavesam S, Muthukumar A, Mani BR, R SS, Pradhabane G, Vn AD, Subramani S, Muthaiah M, Soundappan G.   +12 more
europepmc   +4 more sources

Rifampicin Resistance in Tuberculosis Outbreak, London, England

Emerging Infectious Diseases, 2005
Mycobacterium tuberculosis isolates cultured from 6 patients associated with an isoniazid-resistant M. tuberculosis outbreak acquired rifampicin resistance. The rpoB gene sequence showed that resistance was associated with rare mutations in each isolate.
Claire Jenkins, Alleyna P. Claxton, Robert J. Shorten, Timothy D. McHugh, Stephen H. Gillespie   +4 more
doaj   +4 more sources

Serine/threonine protein kinase mediates rifampicin resistance in Brucella melitensis through interacting with ribosomal protein RpsD and affecting antioxidant capacity [PDF]

mSystems
Brucellosis, a zoonotic disease, has re-emerged in both humans and animals, causing significant economic losses globally. Recently, an increasing number of rifampicin-resistant Brucella strains have been isolated worldwide without detectable mutations in
Yaqin Yuan, Wenqing Ning, Junjie Chen, Jiquan Li, Tianqi Xue, Cuihong An, Lingling Mao, Guangzhi Zhang, Shizhong Zhou, Jiabo Ding, Xiaowen Yang, Jianqiang Ye   +11 more
doaj   +2 more sources